未名医药
(002581)
| 流通市值：40.12亿 | | | 总市值：66.04亿 |
| 流通股本：4.01亿 | | | 总股本：6.60亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 388,846,865.13 | 394,388,874.79 | 215,364,820.62 | 151,911,816.56 |
| 结算备付金 | - | - | - | 0 |
| 拆出资金 | - | - | - | 0 |
| 衍生金融资产 | - | - | - | 0 |
| 应收票据及应收账款 | 124,255,461.9 | 150,954,736.47 | 127,863,301.56 | 149,076,764.07 |
| 其中：应收票据 | 7,951,736.21 | 5,694,425.03 | 6,135,145.44 | 15,432,142.98 |
| 应收账款 | 116,303,725.69 | 145,260,311.44 | 121,728,156.12 | 133,644,621.09 |
| 应收款项融资 | 20,156,983.63 | 17,725,549.41 | 16,267,702.65 | 23,546,518.12 |
| 预付款项 | 9,778,730.09 | 2,969,016.3 | 6,540,323.67 | 4,696,308.15 |
| 应收保费 | - | - | - | 0 |
| 应收分保账款 | - | - | - | 0 |
| 应收分保合同准备金 | - | - | - | 0 |
| 其他应收款合计 | 53,479,635.4 | 52,760,451.63 | 52,821,264.84 | 76,742,042.71 |
| 买入返售金融资产 | - | - | - | 0 |
| 存货 | 81,077,832.89 | 78,916,263.59 | 85,392,119.15 | 85,314,336.34 |
| 合同资产 | - | - | - | 0 |
| 一年内到期的非流动资产 | - | - | 0 | 0 |
| 其他流动资产 | 3,358,580.9 | 3,623,609.04 | 3,354,159.94 | 4,491,581.81 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 721,882,905.32 | 742,267,316.61 | 508,532,507.81 | 496,708,183.14 |
| 非流动资产: | | | | |
| 发放委托贷款及垫款 | - | - | - | 0 |
| 债权投资 | - | - | - | 0 |
| 其他债权投资 | - | - | - | 0 |
| 长期应收款 | - | - | - | 0 |
| 长期股权投资 | 1,144,374,143.94 | 1,088,381,252.18 | 1,293,951,692.52 | 1,354,511,910.16 |
| 其他权益工具投资 | - | - | - | 0 |
| 其他非流动金融资产 | - | - | - | 0 |
| 投资性房地产 | - | - | - | 0 |
| 固定资产 | 285,780,080.74 | 292,679,355.85 | 305,681,819.62 | 335,156,396.68 |
| 在建工程 | 21,055,309.43 | 21,019,342 | 20,887,005.92 | 22,167,382.17 |
| 生产性生物资产 | - | - | - | 0 |
| 油气资产 | - | - | - | 0 |
| 使用权资产 | 303,600.07 | 394,365.09 | 583,860.18 | 773,355.27 |
| 无形资产 | 102,444,893.3 | 104,400,391.39 | 106,360,108.7 | 108,287,826.26 |
| 开发支出 | - | - | - | 0 |
| 商誉 | - | - | - | 0 |
| 长期待摊费用 | 361,683.59 | 711,527.36 | 1,061,371.16 | 1,411,214.94 |
| 递延所得税资产 | 5,706,975.42 | 5,880,949.07 | 5,843,506.96 | 6,122,144.98 |
| 其他非流动资产 | 13,978,249.31 | 13,679,243.19 | 13,045,344.76 | 11,999,535.43 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,574,004,935.8 | 1,527,146,426.13 | 1,747,414,709.82 | 1,840,429,765.89 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 2,295,887,841.12 | 2,269,413,742.74 | 2,255,947,217.63 | 2,337,137,949.03 |
| 流动负债: | | | | |
| 短期借款 | 0 | 10,000,000 | 10,000,000 | 13,837,591 |
| 向中央银行借款 | - | - | - | 0 |
| 吸收存款及同业存放 | - | - | - | 0 |
| 拆入资金 | - | - | - | 0 |
| 交易性金融负债 | - | - | - | 0 |
| 衍生金融负债 | - | - | - | 0 |
| 应付票据及应付账款 | 35,660,435.18 | 35,095,422.3 | 36,888,096.61 | 73,689,801.08 |
| 其中：应付票据 | - | - | - | 0 |
| 应付账款 | 35,660,435.18 | 35,095,422.3 | 36,888,096.61 | 73,689,801.08 |
| 预收款项 | - | - | - | 0 |
| 合同负债 | 6,095,571.95 | 5,713,456.77 | 2,500,000 | 3,589,971.46 |
| 卖出回购金融资产款 | - | - | - | 0 |
| 应付手续费及佣金 | - | - | - | 0 |
| 应付职工薪酬 | 7,951,267.01 | 4,847,344.11 | 4,607,505.24 | 13,540,784.66 |
| 应交税费 | 4,414,231.66 | 4,883,763.02 | 2,661,459.68 | 4,606,533.88 |
| 其他应付款合计 | 10,432,733.93 | 25,703,280.08 | 16,715,142.65 | 21,273,212.42 |
| 应付分保账款 | - | - | - | 0 |
| 保险合同准备金 | - | - | - | 0 |
| 代理买卖证券款 | - | - | - | 0 |
| 代理承销证券款 | - | - | - | 0 |
| 一年内到期的非流动负债 | - | - | - | 0 |
| 其他流动负债 | 0 | - | 2,472,760.31 | 3,070,160.83 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 64,554,239.73 | 86,243,266.28 | 75,844,964.49 | 133,608,055.33 |
| 非流动负债: | | | | |
| 长期借款 | - | - | - | 0 |
| 应付债券 | - | - | - | 0 |
| 优先股 | - | - | - | 0 |
| 永续债 | - | - | - | 0 |
| 租赁负债 | 209,428.52 | 320,436.73 | 516,763.03 | 709,788.51 |
| 长期应付款 | - | - | - | 0 |
| 长期应付职工薪酬 | - | - | - | 0 |
| 预计负债 | 13,197,336.43 | 16,788,572.01 | 13,703,029.13 | 16,094,003.35 |
| 递延收益 | 5,168,505.81 | 5,276,901.24 | 5,385,296.67 | 5,493,692.1 |
| 递延所得税负债 | 7,759,231.54 | 7,426,647.78 | 7,427,091.84 | 7,506,058.44 |
| 其他非流动负债 | - | - | - | 0 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 26,334,502.3 | 29,812,557.76 | 27,032,180.67 | 29,803,542.4 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 90,888,742.03 | 116,055,824.04 | 102,877,145.16 | 163,411,597.73 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 229,145,299 | 229,145,299 | 229,145,299 | 229,145,299 |
| 其他权益工具 | - | - | - | 0 |
| 优先股 | - | - | - | 0 |
| 永续债 | - | - | - | 0 |
| 资本公积 | 881,203,262.29 | 878,378,556.33 | 880,331,410.49 | 873,932,348.51 |
| 减:库存股 | - | - | - | 0 |
| 其他综合收益 | - | - | - | 0 |
| 专项储备 | - | - | - | 0 |
| 盈余公积 | 152,522,396.39 | 152,522,396.39 | 152,522,396.39 | 152,522,396.39 |
| 一般风险准备 | - | - | - | 0 |
| 未分配利润 | 827,493,954.31 | 783,252,768.94 | 785,163,604.86 | 812,867,686.01 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 2,090,364,911.99 | 2,043,299,020.66 | 2,047,162,710.74 | 2,068,467,729.91 |
| 少数股东权益 | 114,634,187.1 | 110,058,898.04 | 105,907,361.73 | 105,258,621.39 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 2,204,999,099.09 | 2,153,357,918.7 | 2,153,070,072.47 | 2,173,726,351.3 |
| 负债和股东权益合计 | 2,295,887,841.12 | 2,269,413,742.74 | 2,255,947,217.63 | 2,337,137,949.03 |
| 公告日期 | 2024-10-30 | 2024-08-28 | 2024-04-30 | 2024-04-30 |
| 审计意见(境内) | | | | 保留意见 |